HIV, the virus responsible for AIDS, has long evaded vaccine development efforts due to its exceptional genetic variability and sophisticated mechanisms that shield it from immune attack. Traditional vaccine approaches, which often stimulate antibodies targeting specific viral strains, have failed to provide durable or broad-spectrum protection. Recognizing these challenges, the collaborative team led by LJI’s Professor Shane Crotty, Ph.D., and Scripps Research Professor William Schief, Ph.D., embarked on an ambitious project reminiscent of monumental scientific endeavors like the Apollo moon missions, requiring iterative innovation and discovery.

The core advance presented by this new vaccine lies in its ability to elicit high titers of “broadly neutralizing antibodies” (bNAbs), a rare class of antibodies capable of recognizing and neutralizing diverse HIV variants. These bNAbs target conserved epitopes on the HIV envelope glycoproteins that remain relatively unchanged across strains, thus circumventing the virus’s antigenic variability. Historically, eliciting bNAbs through vaccination has been an elusive goal, primarily because the immune system seldom generates these antibodies naturally without chronic infection or disease progression.

The vaccine strategy utilizes an innovative immunogen design, integrating stabilized HIV envelope trimers engineered to resemble the native viral spikes. These immunogens are coupled with novel adjuvants to enhance immune activation, including synthetic molecules designed to stimulate key innate immune pathways. This sophisticated vaccine formulation primes B cells to mature along specific developmental pathways, thereby fostering the production of bNAbs with exceptional affinity and breadth.

Preclinical trials in non-human primates demonstrated the vaccine’s capacity to induce the most robust HIV-neutralizing antibody responses ever documented in these models. The animals exhibited sustained antibody titers targeting a broad range of viral strains, translating into significant protection against experimental HIV exposures. Such efficacy in primate models is an encouraging predictor for potential human application, although further clinical evaluation will be essential to confirm safety, immunogenicity, and protective efficacy.

Importantly, the vaccine’s mechanism transcends conventional immune recognition by training immune cells to see beyond HIV’s shield of glycan sugars and variable loops. By focusing immune responses on conserved structural elements hidden beneath this camouflage, the vaccine effectively unmasks the virus, guiding the immune system to mount a potent and broad defense. This approach highlights the critical interplay between immunogen design and antibody maturation processes, providing crucial insights for next-generation vaccine development.

The collaborative effort involved extensive structural biology analyses, including cryo-electron microscopy, to visualize the vaccine-targeted envelope proteins at atomic resolution. These detailed structural insights informed rational immunogen modifications aimed at stabilizing desired conformations that optimally engage the naive B-cell receptor repertoire. Concurrently, longitudinal immunogenicity studies elucidated the kinetics of antibody evolution, informing iterative vaccine boosting strategies to refine and enhance bNAb responses.

This work was supported by multiple prominent funding bodies, including the National Institute of Allergy and Infectious Diseases (NIAID), the Bill and Melinda Gates Foundation, and the International AIDS Vaccine Initiative (IAVI), demonstrating the critical role of sustained investment in high-risk, high-reward scientific endeavors. The synergy of expertise in immunology, structural biology, and vaccine design was essential for surmounting one of the most complex challenges in infectious disease prevention.

Safety considerations remain paramount as the vaccine progresses toward human trials. The current preclinical data suggest a favorable profile, with no observed adverse effects in primate subjects. However, translating these findings to humans entails rigorous phased clinical testing to evaluate potential reactogenicity, immunogenic durability, and protection against diverse HIV clades encountered in endemic regions.

Beyond HIV, the principles advanced in this vaccine platform have broader implications for vaccine science. The paradigm of eliciting broadly neutralizing antibodies through precisely engineered immunogens could inform vaccine strategies against other rapidly mutating pathogens such as influenza, hepatitis C, and emerging viral threats. This approach underscores the growing importance of tailoring immune responses at the molecular level for enhanced effectiveness.

The culmination of more than a decade of research, this study epitomizes the power of multidisciplinary collaboration and cutting-edge technology in transforming scientific possibility into practical solutions. While challenges remain before this vaccine can be widely deployed, the results kindle renewed optimism for controlling the HIV epidemic, which continues to afflict millions worldwide.

Efforts are now underway to translate these promising preclinical outcomes into human clinical trials, an essential step toward validating vaccine efficacy and ultimately curbing a global health crisis. If successful, this HIV vaccine could mark a watershed moment in infectious disease prevention, offering durable and broad protection against a virus that has long defied eradication.

In summary, the innovative HIV vaccine developed by teams at the La Jolla Institute for Immunology and Scripps Research represents a landmark achievement, demonstrating for the first time that vaccination can reliably induce broadly neutralizing antibodies in primates. This milestone paves the way for transformative advancements in HIV prevention and offers tangible hope toward the goal of ending the AIDS epidemic.

Subject of Research: Animals

Article Title: Vaccination elicits HIV broadly neutralizing antibodies in primates

News Publication Date: 30-Jun-2026

Web References:
https://www.nature.com/articles/s41586-026-10837-5
DOI: 10.1038/s41586-026-10837-5

Keywords: Infectious diseases, HIV infections, broadly neutralizing antibodies, vaccine development, immunogen design, adaptive immunity, structural biology, primate studies, HIV vaccine, viral immunology, AIDS prevention, antibody maturation

At the heart of this discovery lies the detailed analysis of the HIV Env C-strand, spanning residues 164 to 172, which serves as a pivotal epitope for neutralizing antibody binding. The study focuses on antibodies isolated from non-human primates vaccinated with Env trimer-liposome immunogens, with particular emphasis on the most broadly neutralizing antibody identified, Q12BBM-069. This antibody exhibits remarkable cross-reactivity across diverse viral strains lacking the Asn130 glycan, a common glycosylation site implicated in immune evasion.

The researchers delineated a distinctive amino acid signature within the C-strand of viruses neutralized by Q12BBM-069: a sequence characterized predominantly as 164-ELRDKKQKV-172. This motif is enriched with basic residues, notably lysines (Lys) and arginines (Arg) at positions 168, 169, and 171, which facilitate strong electrostatic interactions with the antibody’s paratope. These positively charged residues appear crucial for the effective binding and neutralization by Q12BBM-069, underscoring the influence of precise local chemistry on antibody efficacy.

Intriguingly, natural resistance to Q12BBM-069-mediated neutralization correlates with deviations from this consensus sequence, particularly at the aforementioned positions bearing basic amino acids. Viral variants harboring multiple substitutions within the C-strand exhibit resistance, mirroring patterns observed with other apex-targeting broadly neutralizing antibodies (bNAbs) such as VRC26, which struggles to neutralize clade B viruses effectively. This phenomenon highlights the challenge posed by viral diversity in vaccine development.

A conspicuous example of such resistance is found in the clade B HIV-1 isolate WITO.33, whose V2 C-strand sequence deviates significantly—164-VIRDKIQKE-172—bearing substitutions that diminish the presence of positively charged residues key to antibody binding. Notably, Q12BBM-069 fails to neutralize WITO.33, reflecting the profound impact of even subtle sequence variation within the V2 apex on antibody recognition.

Despite this obstacle, the study reveals that other antibodies isolated from vaccinated non-human primates can overcome this sequence variability. The mAb Q7M-675 uniquely neutralizes WITO.33, demonstrating that alternative antibody lineages elicited by the vaccine effectively target the V2 apex despite the divergent sequence. Serum IgG from animals Q7 and Q8 similarly neutralizes WITO.33, suggesting that the immune response encompasses multiple antibodies capable of binding distinct, potentially overlapping epitopes within the Env apex region.

Mapping analyses of these sera emphasize that the neutralization of WITO.33 depends predominantly on the V2 C-strand. To validate this, researchers engineered viral variants with targeted mutations designed to disrupt apex bNAb recognition—specifically I169E/K171E and K168E substitutions—which abolished neutralization by these immune sera. Such precise mutagenesis confirms the critical role of these residues in mediating antibody neutralization.

Further reinforcing the importance of residue 169 in neutralization sensitivity, a single I169R mutation in the WITO.33 background significantly increased susceptibility to Q7M-675 and the polyclonal IgG from animals Q7 and Q8. This finding illuminates the fine balance between epitope variability and immune recognition that governs viral escape and control, presenting a potential target for immunogen design.

The collective data suggest that while natural sequence variation in the HIV Env apex poses challenges to vaccine-induced immunity, it is not insurmountable. Immunization protocols engaging diverse antibody lineages can effectively navigate viral heterogeneity, inducing antibodies that recognize multiple variants of the V2 C-strand. This adaptive breadth is critical for developing vaccines capable of conferring robust protection across global HIV clades.

Moreover, all immunized non-human primates produced serum IgG capable of neutralizing viruses presenting divergent C-strand sequences beyond the primary Q12BBM-069 epitope. This broad neutralization profile indicates the presence of additional antibody populations targeting either alternate sites within the apex or distinct epitopes entirely. Such immunological diversity may augment the overall efficacy of the vaccine by providing a multipronged defense against viral escape.

These findings offer critical molecular blueprints for next-generation HIV vaccines. By incorporating structural and sequence insights into Env trimer-liposome immunogens, researchers can hone vaccines to elicit broadly neutralizing antibodies capable of contending with HIV’s rapid mutation and sequence plasticity. The strategic focus on the V2 apex, particularly the electrostatic features of the C-strand, provides a promising avenue for overcoming natural viral resistance mechanisms.

The study not only highlights the dynamic interplay between viral sequence diversity and antibody binding but also underscores the necessity of inducing a repertoire of antibodies with complementary specificities. Such vaccination strategies could preempt viral escape mutations by targeting conserved structural and chemical features within the Env apex, a site critical to the virus’s infectivity.

In sum, this research represents a significant stride toward a universal HIV vaccine. By resolving the nuanced sequence dependencies governing antibody neutralization at the Env apex, it paves the way for immunogens capable of eliciting potent, broadly cross-reactive antibody responses. These advances carry profound implications for the global effort to curb the HIV epidemic, offering hope for vaccines that can adapt to and neutralize the virus’s formidable diversity.

Subject of Research: HIV vaccine development focusing on broadly neutralizing antibodies targeting the HIV Env apex, particularly the V2 C-strand epitope.

Article Title: Vaccination generates broadly cross-neutralizing antibodies to the HIV Env apex.

Article References: Guenaga, J., Ádori, M., Bale, S. et al. Vaccination generates broadly cross-neutralizing antibodies to the HIV Env apex. Nature (2026). https://doi.org/10.1038/s41586-026-10429-3

DOI: https://doi.org/10.1038/s41586-026-10429-3

Image Credits: AI Generated

Keywords: HIV, broadly neutralizing antibodies, Env apex, V2 C-strand, vaccine design, viral sequence variability, immunogen, neutralization breadth, non-human primates, antibody escape, electrostatic interactions

When SARS-CoV-2, the coronavirus that causes COVID-19, began spreading worldwide in 2020, many research teams immediately set to work developing a vaccine against it. Building on decades of previous work on mRNA technology and on other viral vaccines, including HIV, they achieved their goal within the year. The most widely used mRNA vaccine design contains the genetic instructions for the body to make the spike protein that the virus uses to enter cells. The resulting immune response protects against infection and, more importantly, disease and death. However, developing a vaccine for HIV has proven much more difficult.

“The COVID-19 vaccines were an enormous achievement but the spike protein on SARS-CoV-2 was like low-hanging fruit for vaccinologists,” said Dr. John Moore, professor of microbiology and immunology at Weill Cornell Medicine and part of an international team that has brought biomedicine closer than ever to an HIV vaccine. “It behaves like its counterparts on viruses for which vaccines are relatively easy to develop, such as influenza. Unfortunately, we learned back in the 1990s how hard it is to make an HIV vaccine.”

Building a stable env protein

The goal of immunization with a viral protein, or some portion of it, is to limit infection by teaching the body to generate neutralizing antibodies that bind to these viral proteins and block their interaction with the receptors found on the cell’s surface. These antibodies can also flag virus-infected cells for destruction by other immune system components.

For SARS-CoV-2, this viral target is called the spike protein; its counterpart on HIV is the envelope (Env) protein trimer. But HIV researchers attempting to target Env in the 1990s discovered that when the three-subunit Env protein is produced in the laboratory it promptly falls apart. To create vaccine candidates for HIV, and later SARS-CoV-2 and respiratory syncytial virus (RSV), it was critical to engineer this kind of multi-subunit vaccine to be more stable.

In 1998, with funding from the National Institutes of Health, Dr. Moore launched an HIV vaccine project to tackle this problem. The challenge was engineering an Env protein trimer that was hardier but still resembled the original closely enough to elicit appropriate antibody responses in test animals, and then people. Dr. Moore was soon joined by Rogier Sanders, a graduate student who came from Amsterdam to work on the project as part of his dissertation. The first advance, published in 2000, involved engineering a new chemical bond that helped key trimer components to stick together without distorting their overall structure. The second key development, in 2002, was swapping one amino acid for another in one of the trimer subunits to fix another major source of instability.

Over the next decade, Dr. Sanders, working with Dr. Moore after he returned to Amsterdam, made several more modifications to the Env protein that enabled them to eventually build a truly stable trimer. They named it SOSIP.664, a term reflecting the nature of the successful modifications.

A collaboration with structural biologists Dr. Ian Wilson and Dr. Andrew Ward at Scripps Research in La Jolla provided critical insights by showing what the new trimer designs looked like when viewed by electron microscopy. The project also involved what Dr. Moore refers to as “sheer grunt work”. To find the best mimic of the Env protein as it appears on the surface of HIV, the team obtained genetic information for about 100 different HIV strains from around the world and then synthesized SOSIP.664 trimers from all of them. A battery of laboratory tests and, above all, structural analyses by the Scripps team enabled the researchers to find the genetic sequences that produced the best Env trimer.

This optimal sequence, designated BG505, was isolated from an infant born with HIV in Kenya by Dr. Julie Overbaugh of the Fred Hutch Cancer Center and her colleagues at the University of Nairobi. To help further HIV research, they had shared the information with the International AIDS Vaccine Initiative (IAVI), a co-funder of Dr. Moore’s team at that time.

A final breakthrough occurred when electron microscopy images showed how the assembled trimers were attracting fat molecules, causing them to aggregate into useless clumps. Once the researchers removed that part of the protein, they had the stable, engineered Env protein they wanted. They named it BG505 SOSIP.664.

Eliciting broadly neutralizing antibodies

Another major challenge in developing an HIV vaccine is that the virus mutates rapidly to evade detection by the immune system. Thus, people living with HIV around the world carry different versions of the Env protein. “It’s akin to what we saw with the COVID-19 variants, but much, much worse,” Dr. Moore said. An effective HIV vaccine must coax the immune system to make “broadly neutralizing antibodies” (bNAbs) capable of attacking many forms of the virus. “We know these antibodies exist, because some infected people make them, and we could show they bound to our SOSIP trimers,” added Dr. Moore. He and his colleague, Dr. P.J. Klasse, professor of research in microbiology and immunology at Weill Cornell Medicine, have been studying HIV neutralizing antibodies for over 25 years.

But could BG505 SOSIP.664 and other trimers the team soon made stimulate the production of bNAbs? Early tests in animal models showed that the BG505 trimers elicited antibodies specific for the infant’s strain, but not the bNAbs that neutralize a broad sample of viruses. The quest continued, now guided by ever-increasing knowledge of the underlying immunology.

Now, leading investigators are pursuing a multi-step immunization process known as “germline-targeting” to generate a lasting HIV vaccine response. This strategy involves activating the antibody-producing cells that make precursors of the broad neutralizers, then coaxing those antibodies along a path to full activity. A germline targeting SOSIP trimer, re-designed by the Sanders’ team and designated GT1.1, is in human trials supported by the Gates Foundation. A recent paper reported success in generating the desired bNAb precursors in a group of healthy volunteers. In an accompanying editorial, Weill Cornell professors Drs. Sallie Permar and Patrick Wilson outline why this approach to an HIV vaccine is so promising. Follow-up clinical trials in Africa are in progress or being planned also. The Moore/Sanders team is continuing its multi-year collaboration with the Permar group to further evaluate the GT1.1 trimer at the pre-clinical stage, as the accrued information can inform clinical trial design.

Progress in jeopardy

Projected decreases in NIH support for vaccine research and development, and other reductions in federal spending, could jeopardize these promising advances. Private philanthropy, including from the Gates Foundation, is vital, but can’t fully compensate for federal funding.

“The NIH has funded the basic design and development work for SOSIP trimer vaccines for over 20 years,” said Dr. Moore. “These were competitive grants. Everything is at risk.” But whatever the future holds, he notes how the COVID vaccines used the same principle of engineering stability into the spike protein. “So indirectly, our work on HIV helped make the COVID mRNA vaccines work as well as they did.”